Overview

This trial is active, not recruiting.

Condition amphetamine-related disorders
Treatment bupropion
Phase phase 1
Sponsor National Institute on Drug Abuse (NIDA)
Collaborator University of California, Los Angeles
Start date June 2002
End date September 2003
Trial size 20 participants
Trial identifier NCT00040040, NIDA-CTO-0010-1

Summary

The purpose of this study is to assess potential interactions between intravenous (IV) methamphetamine and oral bupropion.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Masking double-blind
Primary purpose diagnostic

Primary Outcomes

Measure
Psychological effects
time frame:
BP, HR
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: Please contact site director for more details. Exclusion Criteria: Please contact site director for more details.

Additional Information

Official title Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion
Principal investigator Thomas Newton, M.D.
Description This is a human laboratory clinical pharmacology study to assess potential interactions between IV methamphetamine challenge and treatment with oral sustained-release bupropion.
Trial information was received from ClinicalTrials.gov and was last updated in February 2007.
Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).